Biosimilars: Addressing Uncertainties With a New Drug Class
Kenneth G. Saag MD, MSc - 3/13/2017
1 comment / Last Comment: 3/17/2017
Biosimilars promise increased access and decreased prices for patients in need of expensive biologics. However, as with any new category of drug, biosimilars face some uncertainties. Here’s my take.